Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 4/20 | 0.71 |
| ▸ | CDK4 | P11802 | 4/20 | 0.71 |
| ▸ | CCND1 | P24385 | 4/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.71 |
| ▸ | CDK2 | P24941 | 4/20 | 0.71 |
| ▸ | PRKACA | P17612 | 2/20 | 0.71 |
| ▸ | PRKACG | P22612 | 2/20 | 0.71 |
| ▸ | PRKACB | P22694 | 2/20 | 0.71 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424023 | 0.92 | CDK4 (0.71) | CCNE2CDK4CCND1CCNE1CDK2 | |
| Enmd-981693 SCHEMBL608128 | 0.88 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| Enmd-981693 SCHEMBL29350364 | 0.88 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7496386 | 0.86 | CDK4 (0.55) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL8167814 | 0.86 | CCNE2 (0.69) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL9087198 | 0.85 | CDK4 (0.67) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7822250 | 0.83 | CDK4 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL16934843 | 0.83 | CCNE2 (1.00) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL668748 | 0.82 | CCNE2 (0.57) | CCNE2CDK4CCND1CCNE1CDK2 | |
| SCHEMBL7599053 | 0.82 | CCNE2 (0.51) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366040-B1 | AMORPHOUS FORM OF CELL CYCLE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1441772-A2 | POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS | Nektar Therapeutics Al, Corporation (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030143185-A1 | Polymer conjugates of protein kinase C inhibitors | SHEARWATER CORPORATION | 2003-07-31 | — | — | US | disclosed |
| WO-2003037384-A2 | POLYMER CONJUGATES OF PROTEIN KINASE C INHIBITORS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1064279-A1 | SUBSTITUTED BISINDOLYLMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F.HOFFMANN-LA ROCHE AG (CH) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047518-A1 | SUBSTITUTED BISINDOLYMALEIMIDES FOR THE INHIBITION OF CELL PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143185-A1 | Polymer conjugates of protein kinase C inhibitors | PRKCH, PRKCI, PRKCA | CCNE2 2502/4885CDK4 387/4885CCND1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.